2019 Symposium

2018 Symposium

2017 Symposium

2016 Symposium

2015 Symposium

2014 Symposium

2013 Symposium

Previous Symposia

2016 Featured Talks » Comprehensive genomic profiling of sarcomas in 175 adolescents and young adults reveals a distinct spectrum of targetable genomic alterations



Deborah Morosini from MCC Industry Relations on Vimeo.






Deborah Morosini, MD
Vice President, Clinical Development
Foundation Medicine


Dr. Morosini joined Foundation Medicine as vice president of clinical development in 2013, bringing expertise in oncology drug development, clinical genomics and insightful philanthropic activism. Since joining FMI, she has developed a niche specialty in the genomics of adolescent and young adult (AYA) cancer. In 2015 she was named VP of Clinical Affairs and Patient Engagement. Prior to joining Foundation Medicine, Dr. Morosini founded and led the molecular pathology group at Astrazeneca Pharmaceuticals in the division of Oncology Translational Science, where she helped develop and implement biomarker strategies for biomarker driven trials. Prior to Astrazeneca, Dr. Morosini served as director of pathology for Cytomyx (formerly Ardais Corporation), a clinical genomics biotechnology company specializing in the acquisition, evaluation and characterization of ethically acquired human tissue.

Dr. Morosini is a passionate activist and seasoned keynote speaker. Inspired by her late sister and brother in law, Christopher and Dana Reeve, she has devoted her energies to raising awareness and research dollars for cancer research and early detection. She has been a featured spokesperson for numerous non-profit fundraising and government events in oncology and has provided expert commentary for national television and radio broadcasts, including NBC, ABC, CNN and FOX News.

Dr. Morosini earned her BA in English from Mount Holyoke College and her MSW from NYU Graduate School of Social Work. After completing post BA pre-medical studies at Columbia University, she received her MD from Boston University School of Medicine and completed a pathology residency at Boston Medical Center, where she was chief resident. She currently serves on the Board of Directors for the National Comprehensive Cancer Network (NCCN) Foundation, the Bonnie J. Addario Lung Cancer Foundation, the National Patient Advocate Foundation (NPAF) scientific advisory board, Target Cancer, the NHGRI council, and the Cancer Support Community: central New Jersey.